There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mylan (MYL) and Jounce Therapeutics (JNCE) with bullish sentiments.
Mylan (MYL)
Raymond James analyst Elliot Wilbur maintained a Buy rating on Mylan today. The company’s shares closed last Tuesday at $15.50.
According to TipRanks.com, Wilbur is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.5% and a 41.6% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Sol-Gel Technologies, and ANI Pharmaceuticals.
Currently, the analyst consensus on Mylan is a Strong Buy with an average price target of $23.00, which is a 41.1% upside from current levels. In a report issued on August 20, Merrill Lynch also reiterated a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
Jounce Therapeutics (JNCE)
In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Jounce Therapeutics. The company’s shares closed last Tuesday at $7.53.
According to TipRanks.com, Seedhouse is a 5-star analyst with an average return of 19.9% and a 49.5% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, NGM Biopharmaceuticals, and Arcturus Therapeutics.
Currently, the analyst consensus on Jounce Therapeutics is a Moderate Buy with an average price target of $8.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
